CA-SKYHIVE/DEUTSCHE
11.4.2022 13:02:07 CEST | Business Wire | Press release
SkyHive, a workforce technology innovator that delivers powerful insights for improved human capital management (HCM), today announced that Deutsche Bank, Germany’s leading bank, has made a sizable equity investment in the company via its strategic Corporate Venture Capital unit. The funding coincides with SkyHive’s European incorporation and increasing demand from multinational customers.
Michael Ilgner, Global Head of HR & Real Estate at Deutsche Bank, said: “Using data intelligently and with purpose will take human capital management to the next level. SkyHive is addressing a key talent shortage issue observed across all industries and particularly prevalent in financial services. Its value proposition of providing employers with a better understanding of the skills of their workforce and in the market paves the way for improved resource management, workforce upskilling, and employee retention.”
Gil Perez, Chief Innovation Officer at Deutsche Bank and Head of Deutsche Bank Corporate Venture Capital, said: “We are delighted to invest, partner and collaborate with SkyHive. Deutsche Bank’s digital transformation has accelerated the pace and scale we need to upskill our workforce, attract, and recruit the best talent in the market. Our ability to effectively and continually invest in our current and future employees is an integral part of our digital transformation.”
In addition to the investment, SkyHive has invited Karen Meyer, Chief Operating Officer for Deutsche Bank’s HR organization, to participate in SkyHive’s Board of Directors meetings in a non-voting observer capacity.
SkyHive.ai, a Certified B Corporation, combines its real-time, global labor market data with transparent and unbiased artificial intelligence to give companies, government and educators actionable insights into their workforce’s current and emerging skills, skills gaps, industry benchmarks and reskilling options. SkyHive uses a two-pronged approach: skills-first applications and extensible platforms that normalize skills intelligence for companies across existing HCM ecosystems. For individuals, SkyHive’s Skills Passport provides data, insights and upskilling options to ensure users’ skills stay relevant, both today and well into the future.
“Human capital is by far the most untapped potential in today’s modern age,” said SkyHive Founder and CEO Sean Hinton. “Enterprises and communities that are alert to the advancements in strategic workforce solutions can radically transform top and bottom-line growth trajectories by unleashing their workforce’s full capacity. Who you hire, where you hire, what you pay, who you deploy and how you compete are just a few examples of key business decisions that hinge on a deep, continuous and accurate understanding of your constituents’ skills. Our technology uniquely enables this mission-critical capability, and therefore was a strong rationale for Deutsche Bank’s investment.”
The investment from Deutsche Bank will support SkyHive’s growing global operations, particularly the company’s continued expansion in the European market. SkyHive also maintains ongoing partnerships with the likes of World Economic Forum, Workday and Accenture.
About SkyHive
SkyHive is a Certified B Corporation and software provider of global workforce intelligence technology, optimizing labor market efficiencies in real-time for companies, communities, and national economies. Leading enterprises use SkyHive’s cloud-based applications and platforms to power the future of work at its most granular level: skills. SkyHive’s Quantum Labor Analysis™ has been recognized by the World Economic Forum, Gartner, and Forbes for leading efforts in ethical AI and its positive impact on labor economies worldwide. For more information, visit www.skyhive.ai .
About Deutsche Bank
Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific. For more information, visit www.db.com .
About Deutsche Bank Corporate Venture Capital
Deutsche Bank Corporate Venture Capital (CVC) is a cross-divisional & global activity to support startups and entrepreneurs. For more information, visit db.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom